Keytruda Inj and Opdivo Inj approved promptly for off-label use

The Health Insurance Review & Assessment Service(President Seung-Taek Kim, HIRA) decided to approve off-label uses of Keytruda Inj(generic name: pembrolizumab) and Opdivo Inj(generic name: nivolumab), immune checkpoint inhibitors applied to medical institutes at the Multidisciplinary Committee, after evaluating them at the Cancer Deliberation Committee.

This was made to keep the promise made b...